Clinical Significance of Tyrosine Hydroxylase mRNA Transcripts in Peripheral Blood at Diagnosis in Patients with Neuroblastoma

Na Hee Lee; Meong Hi Son; Young Bae Choi; Eunsang Yi; Ji Won Lee; Keon Hee Yoo; Ki Woong Sung; Hong Hoe Koo

doi:10.4143/crt.2015.481

Articles

Page Path: HOME > Cancer Res Treat > Volume 48(4); 2016 > Article

Original Article Clinical Significance of Tyrosine Hydroxylase mRNA Transcripts in Peripheral Blood at Diagnosis in Patients with Neuroblastoma: Na Hee Lee, MD¹, Meong Hi Son, MD², Young Bae Choi, MD³, Eunsang Yi, MD³, Ji Won Lee, MD, PhD³, Keon Hee Yoo, MD, PhD³, Ki Woong Sung, MD, PhD^3,, Hong Hoe Koo, MD, PhD³; Cancer Research and Treatment : Official Journal of Korean Cancer Association 2016;48(4):1399-1407.
DOI: https://doi.org/10.4143/crt.2015.481
Published online: March 24, 2016

¹Department of Pediatrics, CHA Bundang Medical Center, CHA University, Seongnam, Korea

²Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada

³Department of Pediatrics, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea

Correspondence: Ki Woong Sung, MD, PhD Department of Pediatrics, Samsung Medical Center, Sungkyunkwan University School of Medicine, 81 Irwon-ro, Gangnam-gu, Seoul 06351, Korea
Tel: 82-2-3410-3529 Fax: 82-2-3410-0049 E-mail: kwsped@skku.edu

*Na Hee Lee and Meong Hi Son contributed equally to this work.

• Received: December 10, 2015 • Accepted: March 14, 2016

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

10,349 Views
160 Download
16 Web of Science
16 Crossref
17 Scopus

prev next

Full Article

Download PDF

Abstract
Introduction
Materials and Methods
Results
Discussion
Conclusion
NOTES
REFERENCES

Abstract

Purpose
The purpose of this study is to investigate the clinical significance of tyrosine hydroxylase (TH) expression in peripheral blood (PB) at diagnosis in patients with neuroblastoma.
Materials and Methods
TH mRNA expression in PB was measured by reverse transcription quantitative real-time polymerase chain reaction in 210 patients who were newly diagnosed with neuroblastoma from July 2005 to June 2015 and the clinical significance of TH expression in PB at diagnosis was evaluated.
Results
TH expression was positive in 60 patients (28.6%). Fifty of 60 TH-positive patients had metastatic tumors and the remaining 10 had localized tumors. TH expression was associated with high-risk features (i.e., advanced stage, older age, unfavorable pathology, and MYCN amplification) at diagnosis. Among TH-positive patients, higher TH expression level was observed in high-risk patients than in low- or intermediate-risk patients (p=0.035). The probability of 5-year progression-free survival (PFS) was lower in TH-positive patients than in TH-negative patients (63.8±6.9% vs. 94.7±2.1%, p < 0.001). In analysis confined to high-risk patients, the 5-year probability of PFS remained lower in TH-positive patients (55.7±8.2% vs. 89.6±5.8%, p < 0.001). Among TH-positive patients, a higher expression level of TH was associated with a worse outcome. In multivariate analyses, positive TH expression in PB at diagnosis was an independent poor prognostic factor for PFS.
Conclusion
The treatment intensity should be tailored according to TH expression in PB at diagnosis.
Key words: Neuroblastoma, Tyrosine 3-monooxygenase, Polymerase chain reaction

Introduction

Neuroblastoma (NB) is a common childhood solid tumor that presents with clinical heterogeneity. The presentation of NB can range from localized tumors to disseminated forms, which have different prognoses and require different treatment [1,2]. Therefore, determining the disease extent and stage at the time of diagnosis is important. A number of genetic and biological markers have been investigated for detection of minimal levels of NB cells [3]. Tyrosine hydroxylase (TH), which is mainly expressed in sympathetic nervous tissues [4], has been suggested as a candidate marker for detecting minimal levels of neuroblastoma cells in bone marrow (BM) and peripheral blood (PB) [5]. Molecular detection of TH mRNA using reverse transcription quantitative real-time polymerase chain reaction (RT-qPCR) has been proposed as a specific and sensitive method for detection of minimal disease in NB [5-8].

According to our preliminary reports, positive TH expression in PB at diagnosis is a poor prognostic factor [9]. However, the number of patients was small and the follow-up duration was short. In the current study, we evaluated the significance of TH expression in a larger cohort of patients with a longer follow-up period as well as the clinical implications of the level of TH expression among TH-positive patients.

Materials and Methods

Written informed consent for TH analysis was obtained at diagnosis from all patients or guardians. This retrospective study was approved by the Institutional Review Board (IRB) of Samsung Medical Center and the requirement for informed consent was waived (IRB 2014-12-090).

1. Patients

Medical records of all patients who were newly diagnosed with NB over a 10-year period from July 2005 to June 2015 were reviewed retrospectively. Patients were staged according to the International Neuroblastoma Staging System [10] and disease extent was evaluated using computerized tomography (CT), magnetic resonance imaging (MRI), technetium-99 bone scans, bilateral BM aspirates and biopsy specimens, and ¹³¹I- or ¹²³I-metaiodobenzylguanidine (MIBG) scanning. Measurement of TH expression in PB was included in routine evaluation at diagnosis. MYCN amplification was determined using competitive polymerase chain reaction (PCR), RT-qPCR, or fluorescence in situ hybridization. Tumors were classified as histologically favorable or unfavorable according to the International Neuroblastoma Pathology Classification [11]. Measurement of serum lactic dehydrogenase (LDH), ferritin, neuron-specific enolase (NSE), and urine vanillylmandelic acid (VMA) was also included in routine evaluation at diagnosis. Patients were stratified into low-risk, intermediate-risk, and high-risk groups based on age, stage, and MYCN status. Stage 1, 2, and 4S tumors without MYCN amplification were stratified as low-risk tumors whereas stage 4 tumors in patients older than 12 months or any tumors with amplified MYCN were stratified as high-risk tumors. All other tumors were stratified as intermediate-risk.

2. Treatment

Excisional biopsy of the primary tumor was performed at diagnosis for resectable tumors. Otherwise, incisional or percutaneous needle biopsy was performed with definitive surgery after six chemotherapy cycles. Alternating CEDC (cisplatin+etoposide+doxorubicin+cyclophosphamide) and ICE (ifosfamide+carboplatin+etoposide) regimens were used for chemotherapy (Table 1). Patients with low-risk localized tumors underwent surgery with (stage 2) or without (stage 1) six cycles of preoperative or postoperative chemotherapy. Patients with low-risk stage 4S tumors were treated only when there were life-threatening symptoms or the tumor progressed during observation. Patients with intermediaterisk tumors received six cycles of preoperative chemotherapy, surgery, three cycles of postoperative chemotherapy, and 12 cycles of 13-cis-retinoic acid (125 mg/m²/day for 14 days every 4 weeks). Local radiotherapy to the primary site was administered if gross residual tumor remained after surgery. Patients with high-risk tumors received tandem high-dose chemotherapy and autologous stem cell transplantation (HDCT/auto-SCT) after induction treatment (six cycles of preoperative chemotherapy, surgery, and three cycles of postoperative chemotherapy). The CEC (carboplatin+ etoposide+cyclophosphamide) regimen was used for the first HDCT. The second HDCT regimen was TM-TBI (thiotepa+melphalan+total body irradiation) for patients diagnosed up to December 2008. For patients diagnosed from January 2009 onwards, TBI was replaced with high-dose ¹³¹I-MIBG (12 or 18 mCi/kg) to reduce late adverse effects. Local radiotherapy was applied to the primary site in all high-risk patients approximately 6 weeks after the second HDCT/auto-SCT. Differentiation therapy involving 13-cis-retinoic acid with immunotherapy using interleukin 2 (2×10⁶ U/m²/day for 5 days every 4 weeks) was administered until 1 year after HDCT/auto-SCT to reduce relapse from minimal residual tumor cells [12].

3. RT-qPCR for TH expression analysis

PB samples were collected at diagnosis in ethylenediaminetetraacetic acid tubes and mononuclear cells were separated and lysed in TRIzol reagent (Invitrogen Corporation, Carlsbad, CA). RNA was extracted according to the manufacturer’s instructions and 1 μg of RNA was used to generate 20 μL of complementary DNA using an RNA PCR kit (Applied Biosystems, Foster City, CA). RT-qPCR was performed using Real-Q TH Quantification Kits (BioSewoom, Seoul, Korea) on a LightCycler (Roche Diagnostics, Mannheim, Germany). RT-qPCR was performed under the following cycling conditions: denaturation at 95°C for 10 minutes, 45 cycles at 95°C for 10 seconds, 60°C for 10 seconds, and 72°C for 30 seconds, followed by a cooling step at 40°C for 30 seconds. Reactions were performed in a 20-μL volume containing PCR reaction mixture, TaqMan probe (5'-FAM AGCGCAGGAAGCTGATTGCTGAGTAMRA-3'), primer mixture (forward, 5'-TCATCACCTGGTCACCAAGTT-3'; reverse, 5'-GGTCGCCGTGCCTGTACT-3'), 2 μL cDNA, and sterile water. The ABL gene was used as a control gene in RT-qPCR. If the expression value of ABL in the RT-qPCR amplification was less than a copy number of 104, the sample was considered inadequate for RT-qPCR analysis and the RNA extraction was repeated. The quantity of TH transcripts was normalized to the ABL transcript level, and the result was expressed as the ratio of the TH to ABL transcript copy number.

4. Statistics

Pearson’s chi-squared test was used for comparison of frequencies between groups. The Mann-Whitney U test was used for comparison of continuous variables between groups. Progression-free survival (PFS) and overall survival (OS) rates with standard errors were estimated using the Kaplan-Meier method. Relapse was regarded as progression in the statistical analysis. Differences in PFS rates between groups were compared using the log-rank test. Multivariate analyses of prognostic factors for PFS and OS were performed using Cox regression analysis. p-values less than 0.05 were considered significant.

Results

1. Patient characteristics

A total of 210 patients (118 boys and 92 girls) were evaluated for the presence of TH mRNA in PB at diagnosis. The clinical and biological characteristics of patients are shown in Table 2. The median age at diagnosis was 22 months (range, 0 to 232 months) and median follow-up duration was 51 months (range, 1 to 122 months). At diagnosis, 134 patients were older than 12 months, 103 patients had metastatic tumors including four stage 4S tumors, 90 had histologically unfavorable tumors, and 34 had MYCN amplified tumors. Among 89 patients with high-risk tumors, 30 patients used TM-TBI regimen in the second HDCT/auto-SCT and the remaining 59 patients used ¹³¹I-MIBG-TM regimen.

2. RT-qPCR analysis of TH expression in PB

TH expression was positive in PB at diagnosis in 60 of 210 patients (28.6%). The median expression level (TH/ABL ratio) of TH mRNA transcript detected in PB was 1,580×10^-6 (range, 2×10^-6 to 3,711,864×10^-6). Positive TH expression was associated with high-risk features (i.e., advanced stage, older age, unfavorable pathology, and MYCN amplification). The levels of serum LDH, ferritin, NSE, and urine VMA were also higher in TH-positive patients (Table 2). Among 60 TH-positive patients, 50 had metastatic tumors and the remaining 10 had localized tumors (stage 1 in three, stage 2 in two, and stage 3 in five patients). Among the TH-positive patients, a higher TH expression level was associated with advanced stage and high-risk tumor, but not with older age (≥ 12 months) or MYCN amplification (Fig. 1A-D).

3. Survival according to TH expression at diagnosis

Relapse or progression occurred in 19 of 60 TH-positive patients (31.7%), compared with only six of 150 TH-negative patients (4.0%). Lower 5-year probabilities of PFS and OS were observed in TH-positive patients than in TH-negative patients (PFS: 63.8±6.9% vs. 94.7±2.1%, p < 0.001; OS: 70.2± 6.7% vs. 92.4±2.5%, p < 0.001) (Fig. 2A). In analysis confined to only high-risk patients, the 5-year probabilities of PFS and OS remained lower in TH-positive patients (PFS: 55.7±8.2% vs. 89.6±5.8%, p=0.001; OS: 61.4±8.1% vs. 87.2±6.1%, p=0.064) (Fig. 2B). However, in low- and intermediate-risk patients, no difference in the 5-year probabilities of PFS and OS was observed between TH-positive patients and TH-negative patients (PFS: 96.8±1.9% vs. 90.0±8.7%, p=0.447; OS: 100% vs. 94.5±2.5%, p=0.725). Among high-risk patients, there was no difference in the 5-year probabilities of PFS and OS according to the HDCT regimen (TM-TBI vs. ¹³¹I-MIBG-TM) (PFS: 63.3±8.8% vs. 78.7±6.6%, p=0.184; OS: 70.0±8.4% vs. 76.7± 6.4%, p=0.745). In analysis confined to only TH-positive high-risk patients, there was also no difference in survival rates according to the HDCT regimen (PFS: 50.0±12.5% vs. 61.2± 10.5%, p=0.523; OS: 56.3±12.4% vs. 67.0±9.3%, p=0.923). One of 10 TH-positive patients with localized tumors experienced relapse. The results of multivariate analysis for PFS and OS are shown in Table 3. Positive TH expression in PB at diagnosis was an independent factor for PFS (hazard ratio, 6.35; 95% confidence interval, 2.10 to 19.25; p=0.001). The results were similar when the analysis was confined to high-risk patients (hazard ratio, 9.02; 95% confidence interval, 2.06 to 39.50; p=0.004) (Table 4). Among TH-positive patients, a higher expression level of TH was associated with a worse outcome (above median level vs. below median level: 52.9± 10.0% vs. 75.7±8.8%, p=0.075 for 5-year PFS; 55.9±9.6% vs. 89.2±5.9%, p=0.047 for 5-year OS) (Fig. 2C).

Discussion

A number of genetic markers have been investigated for detection of minimal levels of NB cells [13-17]. Viprey et al. [18] reported that the TH, DCX, and PHOX2B genes are the best candidates for detection of circulating NB cells. Corrias et al. [19], who investigated the advantages of measuring multiple molecular targets over a single molecular target, reported that combinations of multiple targets did not add to the predictive power of TH analysis alone. Gilbert et al. [20] also reported that TH might be the one of the most useful molecular targets. In this context, in the current study we measured TH mRNA alone for molecular detection of minimal disease in all patients who were newly diagnosed with NB.

Positive TH expression in PB at diagnosis was associated with high-risk features and worse outcome. More importantly, positive TH expression in PB at diagnosis was an independent poor prognostic factor for PFS. The results were similar when the analysis was confined to high-risk patients. Current staging systems use conventional diagnostic modalities such as CT, MRI, BM biopsy, and various radioisotope scans. Patients are stratified into risk groups based on these staging systems and patients within each risk group are treated uniformly. However, our study showed that outcomes within the high-risk group differ according to TH expression in PB at diagnosis. Previous studies also reported that positive TH expression was a poor prognostic indicator in metastatic NB [13,21,22]. These findings suggest that TH expression at diagnosis might be a significant factor in future methods of risk stratification for NB. Some studies examined the clinical implication of positive TH expression in non-metastatic NB [19,23]. Yanez et al. [23] reported an association of positive TH expression in PB at diagnosis with a higher probability of relapse in patients with non-metastatic NB. These findings suggest that some patients with localized tumors (by conventional diagnostic modalities) might have disseminated micrometastatic disease and therefore might benefit from upstaging and more aggressive treatment [24]. However, in the current study, because only one of 10 TH-positive patients with localized tumor experienced relapse, the significance of TH expression in patients with localized tumors was unclear. Further studies including more patients are needed to evaluate the prognostic importance of TH expression in the PB of patients with localized tumors.

Among TH-positive patients, higher TH expression was associated with advanced stage and high-risk tumor, but not with older age or MYCN amplification, and a higher TH expression level at diagnosis was associated with a worse outcome. Yanez et al. [25] reported that a high level of TH mRNA in PB was a significant independent predictor of event-free survival and OS when detected at diagnosis, post-induction therapy, and at the end of treatment. They proposed inclusion of TH mRNA monitoring throughout the disease course by RT-qPCR as a standard method of disease evaluation that would be helpful in predicting differences in outcome and identify children for whom current treatment is failing or insufficient [25]. The European HR-NBL1/SIOPEN study defined patients with very high TH expression as ultrahigh-risk. These ultrahigh-risk patients showed very poor outcome among the group of high-risk NB patients (PFS, 0%), most of whom underwent single HDCT/auto-SCT following short induction treatment. The authors suggested that patients with very high TH expression are candidates for alternative treatment strategies [22]. In the current study, the prognosis of patients with high TH expression was also poorer than for those with low TH expression, but was not dismal. The relatively better outcome in our patients with high TH expression compared to those in the European HR-NBL1/SIOPEN study might be attributable to the longer induction treatment and more intensive consolidation treatment using tandem HDCT/auto-SCT.

Conclusion

In conclusion, positive TH expression in PB at diagnosis of neuroblastoma is associated with high-risk features and is an independent prognostic factor for poor PFS. Results of the current study suggest that treatment intensity should be tailored according to TH expression in PB at diagnosis.

NOTES

Conflict of interest relevant to this article was not reported.

Acknowledgements

This study was supported by a grant from the Korean Health Technology R&D Project, Ministry of Health & Welfare, Republic of Korea (No. HI13C1521).

Fig. 1.

Association between tyrosine hydroxylase (TH) expression level and clinicopathologic features. (A-C) Among 60 TH-positive patients, a higher level (TH/ABL ratio) of TH mRNA transcript was associated with advanced stage (A), but not older age (≥ 12 months) (B) or MYCN amplification (C). (D) TH expression level was higher in high-risk patients than in low- or intermediate-risk patients (p=0.035).

Fig. 2.

Survival rates according to tyrosine hydroxylase (TH) expression in peripheral blood at diagnosis. (A) The 5-year progression-free survival (PFS) was lower in TH-positive than in TH-negative patients (63.8±6.9% vs. 94.7±2.1%, p < 0.001). (B) In analysis confined to high-risk patients, the probability of 5-year PFS was lower in TH-positive than in TH-negative patients (55.7±8.2% vs. 89.6±5.8%, p=0.001). (C) Among TH-positive patients, a higher expression level of TH was associated with a worse outcome (above median level vs. below median level: 5-year PFS, 52.9±10.0% vs. 75.7±8.8%, p=0.075).

Table 1.

Conventional and HDCT regimens

Regimen/Drug	Dose	Treatment days
Conventional chemotherapy regimen
CEDC
Cisplatin (mg/m²/dose)	60	0
Etoposide (mg/m²/dose)	100	2, 5
Doxorubicin (mg/m²/dose)	30	2
Cyclophosphamide (mg/kg/dose)	30	3, 4
ICE (mg/m²/dose)
Ifosfamide	1,200	0-4
Carboplatin	400	0-1
Etoposide	100	0-4
First HDCT regimen (mg/m²/dose)
Carboplatin	650	–7, –6, –5
Etoposide	650	–7, –6, –5
Cyclophosphamide	1,800	–4, –3, –2
Second HDCT regimen
2004-2008
Thiotepa (mg/m²/dose)	200	–8, –7, –6
Melphalan (mg/m²/dose)	60	–5, –4
TBI (Gy/dose)	3.33	–3, –2, –1
2009-2015
Thiotepa (mg/m²/dose)	200	–6, –5, –4
Melphalan (mg/m²/dose)	60	–3, –2
¹³¹I-MIBG (mCi/kg)	12 or 18	–21

HDCT, high-dose chemotherapy; TBI, total body irradiation; ¹³¹I-MIBG, ¹³¹I-metaiodobenzylguanidine.

Table 2.

Clinical and biological characteristics with respect to TH expression

Variable	TH-negative (n=150)	TH-positive (n=60)	p-value
Sex
Female (n=92)	66 (71.7)	26 (28.3)	0.930
Male (n=118)	84 (71.2)	34 (28.8)
Age
< 12 mo (n=76)	65 (85.5)	11 (14.5)	0.001
≥ 12 mo (n=134)	85 (63.4)	49 (36.6)
INSS stage
Stage 1 (n=35)	32 (91.4)	3 (8.6)	< 0.001
Stage 2 (n=29)	27 (93.1)	2 (6.9)
Stage 3 (n=43)	38 (88.4)	5 (11.6)
Stage 4 (n=99)	49 (49.5)	50 (50.5)
Stage 4S (n=4)	4 (100)	0
Pathology
Favorable (n=115)	91 (79.1)	24 (20.9)	0.008
Unfavorable (n=90)	56 (62.2)	34 (37.8)
Unknown (n=5)	3 (60.0)	2 (40.0)
MYCN
Non-amplified (n=172)	128 (74.4)	44 (25.6)	0.012
Amplified (n=34)	18 (52.9)	16 (47.1)
Unknown (n=4)	4 (100)	0
Risk group
Low (n=65)	59 (90.8)	6 (9.2)	< 0.001
Intermediate (n=57)	50 (87.7)	7 (12.3)
High (n=88)	41 (46.6)	47 (53.4)
LDH (IU/L)	702 (273-10,000)	1,480 (305-15,720)	< 0.001
Ferritin (ng/mL)	80 (8-893)	267 (3-1,639)	< 0.001
NSE (ng/mL)	23 (3-1,443)	99 (7-1,815)	< 0.001
Urine VMA (mg/day)	4.0 (0.2-205.0)	14.7 (0.1-100.0)	< 0.001

Values are presented as number (%) or median (range). TH, tyrosine hydroxylase; INSS, International Neuroblastoma Staging System; LDH, lactate dehydrogenase; NSE, neuron-specific enolase; VMA, vanillylmandelic acid.

Table 3.

Multivariate analysis of factors affecting PFS and OS in all patients

Risk factor	PFS			OS
Risk factor	HR	95% CI	p-value	HR	95% CI	p-value
Age ≥ 12 mo	0.94	0.28-3.18	0.921	0.62	0.20-1.88	0.395
Stage 4	2.51	0.70-9.07	0.160	4.28	1.25-14.63	0.021
Unfavorable pathology	1.40	0.53-3.75	0.499	1.32	0.47-3.69	0.595
MYCN amplification	1.12	0.44-2.84	0.820	2.55	1.10-5.92	0.029
PB TH-positive at diagnosis	6.66	2.25-19.72	0.001	2.14	0.89-5.16	0.089

PFS, progression-free survival; OS, overall survival; HR, hazard ratio; CI, confidence interval; PB, peripheral blood; TH, tyrosine hydroxylase.

Table 4.

Multivariate analysis of factors affecting PFS and OS in high-risk patients

Risk factor	PFS			OS
Risk factor	HR	95% CI	p-value	HR	95% CI	p-value
Age ≥ 12 mo	0.56	0.12-2.62	0.458	0.27	0.07-1.11	0.069
Unfavorable pathology	1.35	0.47-3.89	0.582	2.98	0.75-11.88	0.122
MYCN amplification	0.97	0.37-2.55	0.949	1.84	0.75-4.50	0.181
PB TH-positive at diagnosis	9.02	2.06-39.50	0.004	3.54	1.26-9.93	0.016

PFS, progression-free survival; OS, overall survival; HR, hazard ratio; CI, confidence interval; PB, peripheral blood; TH, tyrosine hydroxylase.

REFERENCES

1. Shimada H, Ambros IM, Dehner LP, Hata J, Joshi VV, Roald B. Terminology and morphologic criteria of neuroblastic tumors: recommendations by the International Neuroblastoma Pathology Committee. Cancer. 1999;86:349–63. Article PubMed
2. Brossard J, Bernstein ML, Lemieux B. Neuroblastoma: an enigmatic disease. Br Med Bull. 1996;52:787–801. Article PubMed
3. Fukuda M, Miyajima Y, Miyashita Y, Horibe K. Disease outcome may be predicted by molecular detection of minimal residual disease in bone marrow in advanced neuroblastoma: a pilot study. J Pediatr Hematol Oncol. 2001;23:10–3. Article PubMed
4. Grima B, Lamouroux A, Boni C, Julien JF, Javoy-Agid F, Mallet J. A single human gene encoding multiple tyrosine hydroxylases with different predicted functional characteristics. Nature. 1987;326:707–11. Article PubMed
5. Naito H, Kuzumaki N, Uchino J, Kobayashi R, Shikano T, Ishikawa Y, et al. Detection of tyrosine hydroxylase mRNA and minimal neuroblastoma cells by the reverse transcription-polymerase chain reaction. Eur J Cancer. 1991;27:762–5. Article PubMed
6. Miyajima Y, Kato K, Numata S, Kudo K, Horibe K. Detection of neuroblastoma cells in bone marrow and peripheral blood at diagnosis by the reverse transcriptase-polymerase chain reaction for tyrosine hydroxylase mRNA. Cancer. 1995;75:2757–61. Article PubMed
7. Kuroda T, Saeki M, Nakano M, Mizutani S. Clinical application of minimal residual neuroblastoma cell detection by reverse transcriptase-polymerase chain reaction. J Pediatr Surg. 1997;32:69–72. Article PubMed
8. Burchill SA, Bradbury FM, Selby P, Lewis IJ. Early clinical evaluation of neuroblastoma cell detection by reverse transcriptase-polymerase chain reaction (RT-PCR) for tyrosine hydroxylase mRNA. Eur J Cancer. 1995;31A:553–6. Article PubMed
9. Lee ST, Ki CS, Sung KW, Kim HJ, Kim JW, Kim SH, et al. Molecular detection of tyrosine hydroxylase in the peripheral blood of patients with neuroblastoma: useful at diagnosis but not predictive of subsequent relapse during off-therapy follow-up. Pediatr Hematol Oncol. 2011;28:16–23. Article PubMed
10. Brodeur GM, Pritchard J, Berthold F, Carlsen NL, Castel V, Castelberry RP, et al. Revisions of the international criteria for neuroblastoma diagnosis, staging, and response to treatment. J Clin Oncol. 1993;11:1466–77. Article PubMed
11. Peuchmaur M, d'Amore ES, Joshi VV, Hata J, Roald B, Dehner LP, et al. Revision of the International Neuroblastoma Pathology Classification: confirmation of favorable and unfavorable prognostic subsets in ganglioneuroblastoma, nodular. Cancer. 2003;98:2274–81. Article PubMed
12. Sung KW, Lee SH, Yoo KH, Jung HL, Cho EJ, Koo HH, et al. Tandem high-dose chemotherapy and autologous stem cell rescue in patients over 1 year of age with stage 4 neuroblastoma. Bone Marrow Transplant. 2007;40:37–45. Article PubMed
13. Burchill SA, Lewis IJ, Abrams KR, Riley R, Imeson J, Pearson AD, et al. Circulating neuroblastoma cells detected by reverse transcriptase polymerase chain reaction for tyrosine hydroxylase mRNA are an independent poor prognostic indicator in stage 4 neuroblastoma in children over 1 year. J Clin Oncol. 2001;19:1795–801. Article PubMed
14. Oltra S, Martinez F, Orellana C, Grau E, Fernandez JM, Canete A, et al. The doublecortin gene, a new molecular marker to detect minimal residual disease in neuroblastoma. Diagn Mol Pathol. 2005;14:53–7. Article PubMed
15. Stutterheim J, Gerritsen A, Zappeij-Kannegieter L, Kleijn I, Dee R, Hooft L, et al. PHOX2B is a novel and specific marker for minimal residual disease testing in neuroblastoma. J Clin Oncol. 2008;26:5443–9. Article PubMed
16. Bozzi F, Luksch R, Collini P, Gambirasio F, Barzano E, Polastri D, et al. Molecular detection of dopamine decarboxylase expression by means of reverse transcriptase and polymerase chain reaction in bone marrow and peripheral blood: utility as a tumor marker for neuroblastoma. Diagn Mol Pathol. 2004;13:135–43. Article PubMed
17. Cheung IY, Vickers A, Cheung NK. Sialyltransferase STX (ST8SiaII): a novel molecular marker of metastatic neuroblastoma. Int J Cancer. 2006;119:152–6. Article PubMed
18. Viprey VF, Lastowska MA, Corrias MV, Swerts K, Jackson MS, Burchill SA. Minimal disease monitoring by QRT-PCR: guidelines for identification and systematic validation of molecular markers prior to evaluation in prospective clinical trials. J Pathol. 2008;216:245–52. Article PubMed
19. Corrias MV, Haupt R, Carlini B, Cappelli E, Giardino S, Tripodi G, et al. Multiple target molecular monitoring of bone marrow and peripheral blood samples from patients with localized neuroblastoma and healthy donors. Pediatr Blood Cancer. 2012;58:43–9. Article PubMed
20. Gilbert J, Norris MD, Marshall GM, Haber M. Low specificity of PGP9.5 expression for detection of micrometastatic neuroblastoma. Br J Cancer. 1997;75:1779–81. Article PubMed PMC
21. Trager C, Vernby A, Kullman A, Ora I, Kogner P, Kagedal B. mRNAs of tyrosine hydroxylase and dopa decarboxylase but not of GD2 synthase are specific for neuroblastoma minimal disease and predicts outcome for children with high-risk disease when measured at diagnosis. Int J Cancer. 2008;123:2849–55. Article PubMed
22. Viprey VF, Gregory WM, Corrias MV, Tchirkov A, Swerts K, Vicha A, et al. Neuroblastoma mRNAs predict outcome in children with stage 4 neuroblastoma: a European HR-NBL1/SIOPEN study. J Clin Oncol. 2014;32:1074–83. Article PubMed
23. Yanez Y, Grau E, Oltra S, Canete A, Martinez F, Orellana C, et al. Minimal disease detection in peripheral blood and bone marrow from patients with non-metastatic neuroblastoma. J Cancer Res Clin Oncol. 2011;137:1263–72. Article PubMed
24. Burchill SA. Micrometastases in neuroblastoma: are they clinically important? J Clin Pathol. 2004;57:14–20. Article PubMed PMC
25. Yanez Y, Hervas D, Grau E, Oltra S, Perez G, Palanca S, et al. TH and DCX mRNAs in peripheral blood and bone marrow predict outcome in metastatic neuroblastoma patients. J Cancer Res Clin Oncol. 2016;142:573–80. Article PubMed PDF

Figure & Data

REFERENCES

Citations

Citations to this article as recorded by

A zinc metabolism-related gene signature for predicting prognosis and characteristics of breast cancer
Jinghui Hong, Mengxin Li, Yichang Chen, Ye Du, Dong Song
Frontiers in Immunology.2024;[Epub] CrossRef
CDK5RAP3 is a novel super-enhancer-driven gene activated by master TFs and regulates ER-Phagy in neuroblastoma
Ran Zhuo, Zimu Zhang, Yanling Chen, Gen Li, Shibei Du, Xinyi Guo, Randong Yang, Yanfang Tao, Xiaolu Li, Fang Fang, Yi Xie, Di Wu, Yang Yang, Chun Yang, Hongli Yin, Guanghui Qian, Hairong Wang, Juanjuan Yu, Siqi Jia, Frank Zhu, Chenxi Feng, Jianwei Wang, Y
Cancer Letters.2024; 591: 216882. CrossRef
A comprehensive overview of liquid biopsy applications in pediatric solid tumors
Ferdinand W. Janssen, Nathalie S. M. Lak, Claudia Y. Janda, Lennart A. Kester, Michael T. Meister, Johannes H. M. Merks, Marry M. van den Heuvel-Eibrink, Max M. van Noesel, Jozsef Zsiros, Godelieve A. M. Tytgat, Leendert H. J. Looijenga
npj Precision Oncology.2024;[Epub] CrossRef
Minimal Infiltrative Disease Identification in Cryopreserved Ovarian Tissue of Girls with Cancer for Future Use: A Systematic Review
Monika Grubliauskaite, M. E. Madeleine van der Perk, Annelies M. E. Bos, Annelot J. M. Meijer, Zivile Gudleviciene, Marry M. van den Heuvel-Eibrink, Jelena Rascon
Cancers.2023; 15(17): 4199. CrossRef
Circulating tumor cells in neuroblastoma: Current status and future perspectives
Ran Yang, Shan Zheng, Rui Dong
Cancer Medicine.2023; 12(1): 7. CrossRef
Targeting of intracellular oncoproteins with peptide-centric CARs
Mark Yarmarkovich, Quinlen F. Marshall, John M. Warrington, Rasika Premaratne, Alvin Farrel, David Groff, Wei Li, Moreno di Marco, Erin Runbeck, Hau Truong, Jugmohit S. Toor, Sarvind Tripathi, Son Nguyen, Helena Shen, Tiffany Noel, Nicole L. Church, Amber
Nature.2023; 623(7988): 820. CrossRef
A novel hypoxia- and lactate metabolism-related signature to predict prognosis and immunotherapy responses for breast cancer by integrating machine learning and bioinformatic analyses
Jia Li, Hao Qiao, Fei Wu, Shiyu Sun, Cong Feng, Chaofan Li, Wanjun Yan, Wei Lv, Huizi Wu, Mengjie Liu, Xi Chen, Xuan Liu, Weiwei Wang, Yifan Cai, Yu Zhang, Zhangjian Zhou, Yinbin Zhang, Shuqun Zhang
Frontiers in Immunology.2022;[Epub] CrossRef
Liquid biomarkers for the management of paediatric neuroblastoma: an approach to personalised and targeted cancer therapy
Ernest Osei, Nidaa Al-Ani, Aladdin Al-Asady, Susan Dang
Journal of Radiotherapy in Practice.2021; 20(2): 217. CrossRef
Construction of a novel methylation‐related prognostic model for colorectal cancer based on microsatellite status
Lichao Cao, Erfei Chen, Hezi Zhang, Ying Ba, Bianbian Yan, Tong Li, Jin Yang
Journal of Cellular Biochemistry.2021; 122(12): 1781. CrossRef
RETRACTED ARTICLE: Cross-HLA targeting of intracellular oncoproteins with peptide-centric CARs
Mark Yarmarkovich, Quinlen F. Marshall, John M. Warrington, Rasika Premaratne, Alvin Farrel, David Groff, Wei Li, Moreno di Marco, Erin Runbeck, Hau Truong, Jugmohit S. Toor, Sarvind Tripathi, Son Nguyen, Helena Shen, Tiffany Noel, Nicole L. Church, Amber
Nature.2021; 599(7885): 477. CrossRef
Clinical Significance of Segmental Chromosomal Aberrations in Patients with Neuroblastoma: First Report in Korean Population
Hana Lim, Meong Hi Son, Ju Kyung Hyun, Hee Won Cho, Hee Young Ju, Ji Won Lee, Keon Hee Yoo, Ki Woong Sung, Hong Hoe Koo
Journal of Korean Medical Science.2020;[Epub] CrossRef
The challenge of defining “ultra‐high‐risk” neuroblastoma
Daniel A. Morgenstern, Rochelle Bagatell, Susan L. Cohn, Michael D. Hogarty, John M. Maris, Lucas Moreno, Julie R. Park, Andrew D. Pearson, Gudrun Schleiermacher, Dominique Valteau‐Couanet, Wendy B. London, Meredith S. Irwin
Pediatric Blood & Cancer.2019;[Epub] CrossRef
Opportunities and challenges of circulating biomarkers in neuroblastoma
Ricky M. Trigg, Jacqui A. Shaw, Suzanne D. Turner
Open Biology.2019;[Epub] CrossRef
Risk stratification of high‐risk metastatic neuroblastoma: A report from the HR‐NBL‐1/SIOPEN study
Daniel A. Morgenstern, Ulrike Pötschger, Lucas Moreno, Vassilios Papadakis, Cormac Owens, Shifra Ash, Claudia Pasqualini, Roberto Luksch, Alberto Garaventa, Adela Canete, Martin Elliot, Aleksandra Wieczorek, Geneviève Laureys, Per Kogner, Josef Malis, Ell
Pediatric Blood & Cancer.2018;[Epub] CrossRef
Favorable prognostic role of tropomodulins in neuroblastoma
Paola Bettinsoli, Giulia Ferrari-Toninelli, Sara Anna Bonini, Michela Guarienti, Davide Cangelosi, Luigi Varesio, Maurizio Memo
Oncotarget.2018; 9(43): 27092. CrossRef
Neuroblastoma in children: Update on clinicopathologic and genetic prognostic factors
Atif A. Ahmed, Lei Zhang, Naresh Reddivalla, Maxine Hetherington
Pediatric Hematology and Oncology.2017; 34(3): 165. CrossRef

PubReader
ePub Link

Cite

CITE: export Copy Download Format; Close

Download Citation

Download a citation file in RIS format that can be imported by all major citation management software, including EndNote, ProCite, RefWorks, and Reference Manager.

Format:

RIS — For EndNote, ProCite, RefWorks, and most other reference management software
BibTeX — For JabRef, BibDesk, and other BibTeX-specific software

Include:

Citation for the content below
Citation and abstract for the content below

Clinical Significance of Tyrosine Hydroxylase mRNA Transcripts in Peripheral Blood at Diagnosis in Patients with Neuroblastoma

Cancer Res Treat. 2016;48(4):1399-1407. Published online March 24, 2016

DOI: https://doi.org/10.4143/crt.2015.481

XML Download

Figure

Clinical Significance of Tyrosine Hydroxylase mRNA Transcripts in Peripheral Blood at Diagnosis in Patients with Neuroblastoma

Fig. 1. Association between tyrosine hydroxylase (TH) expression level and clinicopathologic features. (A-C) Among 60 TH-positive patients, a higher level (TH/ABL ratio) of TH mRNA transcript was associated with advanced stage (A), but not older age (≥ 12 months) (B) or MYCN amplification (C). (D) TH expression level was higher in high-risk patients than in low- or intermediate-risk patients (p=0.035).

Fig. 2. Survival rates according to tyrosine hydroxylase (TH) expression in peripheral blood at diagnosis. (A) The 5-year progression-free survival (PFS) was lower in TH-positive than in TH-negative patients (63.8±6.9% vs. 94.7±2.1%, p < 0.001). (B) In analysis confined to high-risk patients, the probability of 5-year PFS was lower in TH-positive than in TH-negative patients (55.7±8.2% vs. 89.6±5.8%, p=0.001). (C) Among TH-positive patients, a higher expression level of TH was associated with a worse outcome (above median level vs. below median level: 5-year PFS, 52.9±10.0% vs. 75.7±8.8%, p=0.075).

Fig. 1.

Fig. 2.

Clinical Significance of Tyrosine Hydroxylase mRNA Transcripts in Peripheral Blood at Diagnosis in Patients with Neuroblastoma

Regimen/Drug	Dose	Treatment days
Conventional chemotherapy regimen
CEDC
Cisplatin (mg/m²/dose)	60	0
Etoposide (mg/m²/dose)	100	2, 5
Doxorubicin (mg/m²/dose)	30	2
Cyclophosphamide (mg/kg/dose)	30	3, 4
ICE (mg/m²/dose)
Ifosfamide	1,200	0-4
Carboplatin	400	0-1
Etoposide	100	0-4
First HDCT regimen (mg/m²/dose)
Carboplatin	650	–7, –6, –5
Etoposide	650	–7, –6, –5
Cyclophosphamide	1,800	–4, –3, –2
Second HDCT regimen
2004-2008
Thiotepa (mg/m²/dose)	200	–8, –7, –6
Melphalan (mg/m²/dose)	60	–5, –4
TBI (Gy/dose)	3.33	–3, –2, –1
2009-2015
Thiotepa (mg/m²/dose)	200	–6, –5, –4
Melphalan (mg/m²/dose)	60	–3, –2
¹³¹I-MIBG (mCi/kg)	12 or 18	–21

Variable	TH-negative (n=150)	TH-positive (n=60)	p-value
Sex
Female (n=92)	66 (71.7)	26 (28.3)	0.930
Male (n=118)	84 (71.2)	34 (28.8)
Age
< 12 mo (n=76)	65 (85.5)	11 (14.5)	0.001
≥ 12 mo (n=134)	85 (63.4)	49 (36.6)
INSS stage
Stage 1 (n=35)	32 (91.4)	3 (8.6)	< 0.001
Stage 2 (n=29)	27 (93.1)	2 (6.9)
Stage 3 (n=43)	38 (88.4)	5 (11.6)
Stage 4 (n=99)	49 (49.5)	50 (50.5)
Stage 4S (n=4)	4 (100)	0
Pathology
Favorable (n=115)	91 (79.1)	24 (20.9)	0.008
Unfavorable (n=90)	56 (62.2)	34 (37.8)
Unknown (n=5)	3 (60.0)	2 (40.0)
MYCN
Non-amplified (n=172)	128 (74.4)	44 (25.6)	0.012
Amplified (n=34)	18 (52.9)	16 (47.1)
Unknown (n=4)	4 (100)	0
Risk group
Low (n=65)	59 (90.8)	6 (9.2)	< 0.001
Intermediate (n=57)	50 (87.7)	7 (12.3)
High (n=88)	41 (46.6)	47 (53.4)
LDH (IU/L)	702 (273-10,000)	1,480 (305-15,720)	< 0.001
Ferritin (ng/mL)	80 (8-893)	267 (3-1,639)	< 0.001
NSE (ng/mL)	23 (3-1,443)	99 (7-1,815)	< 0.001
Urine VMA (mg/day)	4.0 (0.2-205.0)	14.7 (0.1-100.0)	< 0.001

Risk factor	PFS			OS
Risk factor	HR	95% CI	p-value	HR	95% CI	p-value
Age ≥ 12 mo	0.94	0.28-3.18	0.921	0.62	0.20-1.88	0.395
Stage 4	2.51	0.70-9.07	0.160	4.28	1.25-14.63	0.021
Unfavorable pathology	1.40	0.53-3.75	0.499	1.32	0.47-3.69	0.595
MYCN amplification	1.12	0.44-2.84	0.820	2.55	1.10-5.92	0.029
PB TH-positive at diagnosis	6.66	2.25-19.72	0.001	2.14	0.89-5.16	0.089

Risk factor	PFS			OS
Risk factor	HR	95% CI	p-value	HR	95% CI	p-value
Age ≥ 12 mo	0.56	0.12-2.62	0.458	0.27	0.07-1.11	0.069
Unfavorable pathology	1.35	0.47-3.89	0.582	2.98	0.75-11.88	0.122
MYCN amplification	0.97	0.37-2.55	0.949	1.84	0.75-4.50	0.181
PB TH-positive at diagnosis	9.02	2.06-39.50	0.004	3.54	1.26-9.93	0.016

Table 1. Conventional and HDCT regimens

HDCT, high-dose chemotherapy; TBI, total body irradiation; ¹³¹I-MIBG, ¹³¹I-metaiodobenzylguanidine.

Table 2. Clinical and biological characteristics with respect to TH expression

Table 3. Multivariate analysis of factors affecting PFS and OS in all patients

PFS, progression-free survival; OS, overall survival; HR, hazard ratio; CI, confidence interval; PB, peripheral blood; TH, tyrosine hydroxylase.

Table 4. Multivariate analysis of factors affecting PFS and OS in high-risk patients

PFS, progression-free survival; OS, overall survival; HR, hazard ratio; CI, confidence interval; PB, peripheral blood; TH, tyrosine hydroxylase.